Gencor Pacific, Inc. – Trademark Portfolio
Entity Type: 03
Gencor Pacific, Inc. holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 32 (Light Beverages) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include TESTOFEN, GENOPAUSE, and SLIMALUMA. The owner is based in Anaheim, CA.
Suite B
920 E Orangethorpe
Anaheim, CA 92801
Showing of trademarks Trademarks
Trademark Classifications
Gencor Pacific, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Frequently Asked Questions
How many trademarks does Gencor Pacific, Inc. have?
Gencor Pacific, Inc. has 12 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 abandoned, 7 cancelled.
What trademark classes does Gencor Pacific, Inc. file in?
Gencor Pacific, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 32 (Light Beverages), Class 30 (Staple Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Gencor Pacific, Inc.'s most well-known trademarks?
Gencor Pacific, Inc.'s registered trademark portfolio includes well-known marks such as TESTOFEN, GENOPAUSE, and SLIMALUMA. These are among 3 currently registered trademarks in the portfolio.
What is Gencor Pacific, Inc.'s trademark registration success rate?
Gencor Pacific, Inc. has a 25% trademark registration rate, with 3 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.